Metabolic & Cardiometabolic
GLP-1 receptor agonists improves MASH / NASH (steatohepatitis)
In plain terms: Can GLP-1 drugs help fatty-liver disease (MASH/NASH), including the scarring?
Part of: 💊 GLP-1 Drugs
Yes for resolving the inflammation — robustly shown for semaglutide and tirzepatide; the harder fibrosis (scarring) benefit was null in early phase-2 but reached significance in the large phase-3 ESSENCE trial.
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: All trials, pooled (Meta-analysis)
How the studies fall
The evidence (12)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Alzaki 2026 · Cureus | meta-analysis | supports | moderate | Across seven biopsy-confirmed MASH RCTs, GLP-1 (semaglutide) and GIP/GLP-1 (tirzepatide) agonists improved histologic MASH resolution, with semaglutide achieving dual endpoints in phase 3 ESSENCE. |
| Armstrong 2016 · Lancet | RCT | supports | moderate | LEAN phase-2: liraglutide steatohepatitis resolution 39% vs 9% placebo with no fibrosis worsening; small (n=52). |
| Sun 2024 · Drugs | meta-analysis | supports | moderate | 24-wk NAFLD NMA: GLP-1RA improve hepatic steatosis/enzymes vs placebo; shorter horizon limits fibrosis read. |
| McGuire 2025 · N Engl J Med | RCT | supports | low | SOUL (CV trial) supports systemic cardiometabolic benefit relevant to liver-heart axis; not a liver-histology endpoint. |
| Newsome 2021 · N Engl J Med | RCT | mixed | moderate | Authors' reply reaffirming phase-2 result: strong NASH resolution, fibrosis endpoint not met — honest limitation. |
| Zhou 2024 · Metabolism | meta-analysis | mixed | high | NMA of MASLD drugs: GLP-1RA and polyagonists improve histology/resolution; THR-beta/FGF21 stronger for fibrosis specifically. |
| Newsome 2025 · N Engl J Med | RCT | supports | high | ESSENCE phase-3 (240wk): semaglutide 2.4mg — steatohepatitis resolution 62.9% vs 34.3% AND fibrosis improvement 36.8% vs 22.4% (both P<0.001). |
| Loomba 2024 · N Engl J Med | RCT | supports | high | SYNERGY-NASH: tirzepatide MASH resolution 44-62% vs 10% placebo (dose-dependent, P<0.001); fibrosis signals favorable. |
| 2026 venue: JHEP Rep · JHEP Rep | meta-analysis | supports | high | SR/MA of GLP-1RA in MASH w/ fibrosis: consistent steatohepatitis resolution; pooled fibrosis benefit now emerging. |
| Damen 2026 · Ann Intern Med | meta-analysis | supports | moderate | ACP review notes obesity pharmacotherapy improves obesity-linked steatotic liver disease markers. |
| Amorim 2026 · Chronic Dis Transl Med | observational | supports | moderate | Review: liraglutide (LEAN), semaglutide (phase-2/ESSENCE), tirzepatide (SYNERGY) all improve MASH; durability of fibrosis benefit a gap. |
| Newsome 2021 · N Engl J Med | RCT | mixed | high | Phase-2 semaglutide: NASH resolution 59% vs 17% placebo (P<0.001) BUT fibrosis improvement not significant (43% vs 33%, P=0.48). |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.